Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76782 | 0.87 | ALDH1A1 (0.55) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL5308587 | 0.87 | ALDH1A1 (0.55) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL10087839 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL10087840 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL17866537 | 0.84 | PRKCA (0.49) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL124736 | 0.82 | — | — | |
| SCHEMBL17866517 | 0.81 | ALDH1A1 (0.47) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL17866510 | 0.81 | PRKCA (0.50) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL12662795 | 0.81 | ALDH1A1 (0.43) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL17877418 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | ALDH1A1 74/4885LMNA 2321/4885PRKCA 4646/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | ALDH1A1 432/4885LMNA 1099/4885PRKCA 3981/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | ALDH1A1 307/4885LMNA 1728/4885PRKCA 4414/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | ALDH1A1 760/4885LMNA 3322/4885PRKCA 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.